Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q2 2022 Results Conference Call August 3, 2022 8:30 AM ET
Company Participants
Nareg Sagherian - ED, IR
Jerry Durso - President and CEO
Linda Richardson - Chief Commercial Officer
Dr. Michelle Berrey - President of Research & Development and Chief Medical Officer
Andrew Saik - CFO
Conference Call Participants
Yasmeen Rahimi - Piper Sandler
Kelechi Chikere - Jefferies
Steve Seedhouse - Raymond James
Thomas Smith - SVB Securities
Jon Wolleben - JMP Securities
Mayank Mamtani - B. Riley Securities
Ellie Merle - UBS
Matt Dellatorre - Goldman Sachs
Operator
Hello. Thank you for standing by and welcome to the Second Quarter Intercept Pharmaceuticals Earnings Call. At this time all participants are in listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference may be recorded.
I would now like to hand the conference over to your speaker today, Nareg Sagherian, Executive Director, Investor Relations. Please go ahead.
Nareg Sagherian
Thank you. Good morning and thank you for joining us on today's call. This morning, we issued a press release announcing our second quarter 2022 results and business update, which is available on our website at interceptpharma.com.
Before we begin our discussion, I'd like to note that during our call, we will be making forward-looking statements, including statements regarding our food product and clinical development program; certain regulatory matters, and our strategy, prospects, financial guidance and future commercial and financial performance. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call, and we undertake no obligation to update such statements, except as required by law.
These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. Some but not necessarily all of the risk factors that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this morning's press release and in our periodic public filings with the SEC.
Today's call will begin with prepared remarks from our President and CEO, Jerry Durso; our Chief Commercial Officer, Linda Richardson; President of Research and Development and Chief Medical Officer, Dr. Michelle Berrey; and Chief Financial Officer, Andrew Saik. We will then open the call to take questions. Please limit yourself to one initial question in order to allow time for all questions to be addressed.